The U.S. Food and Drug Administration has granted Orphan Drug Designation to Ever Supreme Bio Technology’s allogeneic CAR-T candidate, CAR001, for malignant glioma. This move gives Ever Supreme a wider clinical and commercial path. The FDA expanded the indication from just glioblastoma to all malignant gliomas. That’s rare in this tough field. 經濟日報 reports that Ever Supreme first applied for orphan status for glioblastoma (GBM). The final FDA decision covers the broader malignant glioma group. That means more patients could benefit.
September’s numbers show the company’s momentum. Ever Supreme reported consolidated revenue of NT$110 million (about $3.4 million). That’s a third straight monthly record for 2026. Revenue jumped 21.26% year-over-year. Third-quarter revenue hit NT$319 million (about $10.0 million), up 18.15% from the previous quarter and 20.83% from last year. For the first three quarters, revenue reached NT$779 million (about $24.4 million), a 17.64% increase over the same period last year. Growth comes from three main businesses: cell storage, cell preparation services, and CDMO operations.
Taiwan Bio Weekly notes that Ever Supreme Bio is among the first Taiwanese companies to actively develop in vivo CAR-T technologies, reflecting a broader industry shift toward next-generation CAR-T platforms.
CAR001’s regulatory leap and platform edge
The FDA’s orphan status for CAR001 does more than check a box. By widening the scope from glioblastoma to all malignant gliomas, the agency has opened up bigger clinical and licensing opportunities for Ever Supreme. Malignant glioma is a fast-growing brain tumor. After recurrence, patients have few options. Orphan Drug Designation brings real benefits: waived marketing application fees, tax credits for clinical research, and, if approved, seven years of U.S. market exclusivity. Recent coverage by 經濟日報 details these incentives.
CAR001 uses an allogeneic γδ T cell, off-the-shelf CAR-T platform. Unlike autologous CAR-T therapies, which take weeks to make for each patient, Ever Supreme’s method uses ready-made cells from healthy donors. This cuts waiting times. It also means more consistent products and a supply that can scale. That matters for cancer care. The ongoing Phase IIa trial is enrolling patients with advanced or relapsed/refractory solid tumors. These include glioblastoma multiforme, colorectal cancer, triple-negative breast cancer, and non-small cell lung cancer. The trial plans to enroll 27 subjects.
Dual-engine strategy and licensing ambitions
Chairman Liu Chu-Chi has set the direction. Ever Supreme runs a dual-track model. CDMO services and cell therapy R&D move in parallel. CDMO and cell services bring in cash. That cash funds new drug development. The CAR001 pipeline is the company’s global bet. As the Phase IIa trial moves forward, Ever Supreme is collecting clinical data. The company is also planning for multi-country, multi-center trials and licensing deals. The U.S. orphan status will be used with clinical data to boost the company’s position in future licensing talks.
In independent reporting, Ever Supreme Bio directly linked the FDA orphan designation to its plans for global commercialization and international licensing of CAR001, emphasizing that the broader malignant glioma indication leaves room for further clinical expansion beyond GBM.
Market analysts say if CAR001 shows early signs of working in the current trial, the mix of orphan status and off-the-shelf advantages could give Ever Supreme more leverage in global deals. The off-the-shelf approach, if it works, could finally solve the cost and supply problems that have held back autologous CAR-T therapies in solid tumors. This challenge has come up in reported cases of next-generation cell therapies.
September revenue broke the NT$110 million mark. Two straight quarters of double-digit growth show the company’s cash engine is running strong. Ever Supreme is now set to speed up CAR001’s global push and pursue licensing on its own terms. Few companies reach this point. Regulatory wins, platform innovation, and strong financials have lined up. The next step will show if Ever Supreme’s dual-engine model can deliver both science and business breakthroughs in a field where most rivals have stalled. The test starts now.
